Marinus Pharmaceuticals, Inc. (MRNS): Price and Financial Metrics

MRNS POWR Grades

• MRNS scores best on the Momentum dimension, with a Momentum rank ahead of 78.35% of US stocks.
• MRNS's strongest trending metric is Quality; it's been moving down over the last 179 days.
• MRNS's current lowest rank is in the Stability metric (where it is better than 5.18% of US stocks).

MRNS Stock Summary

• With a price/sales ratio of 17.91, MARINUS PHARMACEUTICALS INC has a higher such ratio than 93.74% of stocks in our set.
• Revenue growth over the past 12 months for MARINUS PHARMACEUTICALS INC comes in at -21.83%, a number that bests only 10.64% of the US stocks we're tracking.
• Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MRNS comes in at -24.07% -- higher than that of only 17.09% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to MARINUS PHARMACEUTICALS INC are PXLW, VERU, CDXS, BGRY, and IMGN.
• Visit MRNS's SEC page to see the company's official filings. To visit the company's web site, go to www.marinuspharma.com.

MRNS Valuation Summary

• In comparison to the median Healthcare stock, MRNS's price/earnings ratio is 144.4% lower, now standing at -10.7.
• MRNS's price/sales ratio has moved NA NA over the prior 107 months.

Below are key valuation metrics over time for MRNS.

MRNS Growth Metrics

Its 5 year net income to common stockholders growth rate is now at -157.54%.
• Its year over year net cashflow from operations growth rate is now at -6.2%.
• Its 4 year price growth rate is now at 30.43%.

Over the past 33 months, MRNS's revenue has gone up $19,836,000.

The table below shows MRNS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	19.836	-112.722	-15.465
2022-06-30	27.61	-77.674	-106.606
2022-03-31	27.725	-66.957	-90.996
2021-12-31	15.345	-55.477	-98.776
2021-09-30	15.372	-50.125	-87.94
2021-06-30	5.429	-69.997	-84.092

MRNS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• MRNS has a Quality Grade of D, ranking ahead of 11.62% of graded US stocks.
• MRNS's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
• PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with MRNS.

The table below shows MRNS's key quality metrics over time.